Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
50.97 +0.07 (+0.14%) 10:50 ET [NASDAQ]
50.96 x 391 51.14 x 280
Realtime by (Cboe BZX)
50.96 x 391 51.14 x 280
Realtime 50.10 -0.80 (-1.57%) 08:12 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
50.76
Day High
51.40
Open 51.30
Previous Close 50.90 50.90
Volume 259,876 259,876
Avg Vol 3,138,766 3,138,766
Stochastic %K 39.72% 39.72%
Weighted Alpha +0.53 +0.53
5-Day Change -0.58 (-1.14%) -0.58 (-1.14%)
52-Week Range 45.80 - 60.12 45.80 - 60.12
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,586,888
  • Shares Outstanding, K 2,526,265
  • Annual Sales, $ 47,922 M
  • Annual Income, $ 6,016 M
  • EBIT $ 10,112 M
  • EBITDA $ 13,993 M
  • 60-Month Beta 0.57
  • Price/Sales 2.87
  • Price/Cash Flow 9.49
  • Price/Book 1.52

Options Overview Details

View History
  • Implied Volatility 38.35% ( +0.01%)
  • Historical Volatility 27.79%
  • IV Percentile 97%
  • IV Rank 68.08%
  • IV High 48.01% on 04/08/25
  • IV Low 17.75% on 05/13/24
  • Put/Call Vol Ratio 0.39
  • Today's Volume 25
  • Volume Avg (30-Day) 1,346
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 24,753
  • Open Int (30-Day) 35,409

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.90
  • Number of Estimates 7
  • High Estimate 0.98
  • Low Estimate 0.85
  • Prior Year 0.96
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.70 +6.74%
on 04/09/25
Period Open: 56.90
56.93 -10.57%
on 03/25/25
-5.99 (-10.52%)
since 03/21/25
3-Month
47.70 +6.74%
on 04/09/25
Period Open: 51.69
60.12 -15.30%
on 03/10/25
-0.77 (-1.50%)
since 01/21/25
52-Week
45.80 +11.17%
on 12/16/24
Period Open: 46.30
60.12 -15.30%
on 03/10/25
+4.62 (+9.97%)
since 04/19/24

Most Recent Stories

More News
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?

AstraZeneca AZN will report its first-quarter 2025 earnings on April 29, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.68 billion and $1.10 per share, respectively....

AZN : 67.67 (+0.12%)
TEVA : 13.28 (-2.71%)
AMGN : 277.09 (-0.07%)
SNY : 50.93 (+0.06%)
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

REGN : 567.10 (+0.70%)
SNY : 50.93 (+0.06%)
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

J&J JNJ began the earnings season for the drug and biotech sector this week. Pfizer PFE announced the discontinuation of its danuglipron weight loss pill program. The European Commission granted marketing...

JNJ : 157.74 (+0.17%)
RHHBY : 39.0300 (+0.33%)
PFE : 22.15 (+0.05%)
SNY : 50.93 (+0.06%)
This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now?

Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares?

MRK : 77.86 (-0.18%)
RXRX : 5.58 (+1.45%)
RHHBY : 39.0300 (+0.33%)
SNY : 50.93 (+0.06%)
Why You Shouldn't Bet Against Sanofi (SNY) Stock

One stock that might be an intriguing choice for investors right now is Sanofi SNY. This is because this security in the Large Cap Pharmaceuticals space is seeing solid earnings estimate revision activity,...

SNY : 50.93 (+0.06%)
All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now?

The U.S. economy is "perilously close to slipping into recession" because of President Donald Trump's tariffs, according to JPMorgan Chase chief economist Michael Feroli. Should investors worry? I can...

GOLD : 20.59 (+2.08%)
UAL : 64.80 (-2.26%)
NRG : 94.11 (-3.83%)
PNC : 149.42 (-1.91%)
IRM : 82.54 (-1.98%)
JPM : 228.95 (-1.30%)
BRK.A : 766,639.00 (-1.57%)
JNJ : 157.74 (+0.17%)
KHC : 29.75 (+0.98%)
BRK.B : 510.00 (-1.58%)
BRK.TO : 38.20 (-1.50%)
UNH : 434.00 (-4.43%)
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and the expanded...

AZN : 67.67 (+0.12%)
JNJ : 157.74 (+0.17%)
NVS : 111.39 (+0.48%)
PFE : 22.15 (+0.05%)
SNY : 50.93 (+0.06%)
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce...

BAYRY : 5.9550 (-1.08%)
CORT : 63.89 (+2.65%)
ALNY : 236.02 (+0.62%)
SNY : 50.93 (+0.06%)
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

REGN : 567.10 (+0.70%)
SNY : 50.93 (+0.06%)
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...

AZN : 67.67 (+0.12%)
JNJ : 157.74 (+0.17%)
NVS : 111.39 (+0.48%)
PFE : 22.15 (+0.05%)
SNY : 50.93 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 52.17
2nd Resistance Point 51.91
1st Resistance Point 51.40
Last Price 50.93
1st Support Level 50.63
2nd Support Level 50.37
3rd Support Level 49.86

See More

52-Week High 60.12
Fibonacci 61.8% 54.65
Fibonacci 50% 52.96
Fibonacci 38.2% 51.27
Last Price 50.93
52-Week Low 45.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro